Mikhail Blagosklonny’s Contribution To Cancer And Aging Research

Roswell Park Cancer Institute continues to benefit from the visionary leadership of Mikhail Blagosklonny for the 8th consecutive year. Mikhail joined the institution in 2009 from Ordway Research Institute in Albany, New York.

Mikhail is a seasoned expert on oncology. His research focuses on cancer and aging, especially targeted cancer therapies. His studies have always zeroed in on understanding how these therapies protect healthy cells from being damaged by cancer cells during chemotherapy sessions. Moreover, he has also dedicated a good part of his career to study about the underlying mechanism of aging. Mikhail has also studied about various anti-aging drugs and analyzed their effectiveness.

The scientist became famous when he made his TOR signaling hypothesis public. According to the hypothesis, the scientist believes that TOR signaling plays an instrumental role in cancer and aging. He notes that it is possible to use certain cancer drugs to treat aging since the two diseases are caused by TOR signaling. Most studies on the same have continued to show positive results with many researchers confirming that rapamycin can be used to enhance the lives of cancer patients. Even though some scientists do not believe in cancer therapies, Mikhail has continued to be a committed advocate for the use of the cancer drug.

Know more: http://gettingstronger.org/tag/mikhail-blagosklonny/

Mikhail has a sound educational background. The researcher pursued his M.D. in internal medicine from the First Pavlov State Medical University in Russia. After graduating, he rejoined the St. Petersburg-based University to pursue his doctorate in experimental medicine and cardiology. Before joining Roswell Park Cancer Institute, Mikhail worked for New York Medical College and Ordway Research Institute where he was an associate professor of Medicine and senior scientist respectively.

In addition, the scientist has been editing many medical-related articles by virtue of being editor-in-chief of Oncotarget, Cell Cycle, and Aging. At Cancer Biology & Therapy, he works as an associate editor while at Cell Death & Differentiation, he is a member of the editorial board. Mikhail Blagosklonny is also a respected author. He has published many peer-reviewed papers. The researcher is optimistic that they will be able to develop drugs that can treat cancer. Visit classroomvoices.org to read more about Mikhail.